VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a biomedical technology company developing a bioelectronic therapy for inflammatory diseases, announced today the relocation of its corporate headquarters to Mann Biomedical Park in Valencia, California. The move equips the company with additional offices and creates dedicated space for their maturing R&D, clinical and operational capabilities. SetPoint joins Boston Scientific, MannKind Corporation, Quallion and the Alfred Mann Foundation on the 167-acre campus dedicated to innovation in biomedical research.
SetPoint’s new headquarters provides more than 14,000 square feet for the company’s 25 full-time employees, doubling the size of the company’s previous location, also in Valencia. The facility makes room for additional employees as the company grows and allows the company to expand its research and development lab and machine shop and enhance its quality and operations capabilities as the company prepares for clinical trials with its new proprietary bioelectronic medicine platform.
“SetPoint’s move is a milestone for the company as we mature from a start-up company to a world-class innovator in bioelectronic medicine,” said Anthony Arnold, Chief Executive Officer of SetPoint Medical. “The experience among the SetPoint team, along with this state-of-the-art facility, creates an environment where we can best serve our customers and bring to market a safe and effective bioelectronic therapy for chronic inflammatory diseases.”
The campus, originally a secret Lockheed R&D facility, now known as Mann Biomedical Park, was recently purchased by an investment group as a setting dedicated to medical device innovation. The 167-acre campus provides a park-like setting close to major transportation infrastructure and medical device companies like Boston Scientific, Medtronic, Advanced Bionics, St. Jude Medical and others.
SetPoint is developing a novel proprietary bioelectronic medicine platform to treat a variety of inflammation-mediated autoimmune diseases, by activating the body’s natural Inflammatory Reflex to produce a systemic anti-inflammatory effect. The emerging field of bioelectronic medicine aims to address unmet patient needs utilizing digital dose delivery to modulate disease pathways historically treated with drugs.
About SetPoint Medical
SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint’s approach is intended to offer patients and providers an alternative for the treatment of RA and other chronic inflammatory diseases with less risk and cost than drug therapy. SetPoint’s therapy is also being evaluated in an open-label clinical study for Crohn’s Disease.
SetPoint is developing a novel bioelectronic medicine platform consisting of an implantable miniature neuromodulation device and iPad prescription pad application. The implantable device stimulates the vagus nerve to activate the body’s natural Inflammatory Reflex, which is intended to produce a potent systemic anti-inflammatory effect. The company has published positive results from a first-in-human open-label proof-of-concept trial in rheumatoid arthritis in Proceedings of the National Academy of Sciences (PNAS) and presented positive results at the American College of Rheumatology meeting. Current investors in the company include Morgenthaler Ventures, Flare Capital Partners, Topspin Partners, Medtronic, GlaxoSmithKline’s Action Potential Venture Capital Limited and Boston Scientific. For more information, visit www.setpointmedical.com.